Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05769699

Serum Biomarkers in Parkinson's Disease at Different Stages

* Determine clinical characteristics of parkinsonian patients in various stages of disease; * Measure peripheral neurodegeneration, synaptic, and inflammation biomarkers in a population of parkinsonian patients at various stages of disease. * Measure vesicular neurodegeneration, synaptic and inflammation biomarkers

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Parkinson Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Movement Disorders Nervous System Diseases Neurodegenerative Diseases Parkinsonian Disorders Synucleinopathies

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients diagnosed with idiopathic PD according to Movement Disorders Society (MDS) criteria;
  • Age: 18-80 years;
  • Signature of informed consent to participate in this study

Exclusion criteria

.

  • Women pregnant
  • Inflammatory or autoimmune diseases

Treatment and study plan

Blood sample

Procedure

blood sample

Primary outcomes

  1. Determine clinical characteristics of parkinsonian patients in various stages of disease

    Time frame: 3 years

    Determine clinical characteristics of parkinsonian patients in various stages of disease by means of MDS-UPDRS score changes.

  2. Determine clinical characteristics of parkinsonian patients in various stages of disease

    Time frame: 3 years

    Determine clinical characteristics of parkinsonian patients in various stages of disease by means of NMS score changes.

  3. Determine biooogical characteristics of parkinsonian patients in various stages of disease

    Time frame: 3 years

    dosage of serum IL-1b, IL6, IL-5, IL-4, IL17, TNFa, IFNg, IL10, total-alpha-synuclein, NfL, BDNF (ng/ml for all)

Study contacts

Contact information is provided by the study sponsor or research team.

Flavia Torlizzi

CONTACT

[email protected]

0630156433

Giulia Di Lazzaro, MD

CONTACT

[email protected]

0630154303

Sponsors and collaborators

Lead sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Other

Registry information

Important dates

Study start
2022
Primary completion
2023
Study completion
2027
First posted
Mar 15, 2023
Registry last updated
Mar 15, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.